Discounted Cash Flow (DCF) Analysis Levered

Plus Therapeutics Inc

Plus Therapeutics Inc (PSTV)

$2.54
0.05 (+2.01%)

Free Cash Flow

Year
A/P
2013
Actual
2014
Actual
2015
Actual
2016
Actual
2017
Actual
2018
Actual
2019
Actual
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
Revenue 12.207.6011.6611.386.416.657.006.756.516.286.055.84
Revenue (%)
Operating Cash Flow -34.56-30.33-20.47-19.53-18.13-11.98-5.91-15.20-14.66-14.14-13.63-13.15
Operating Cash Flow (%)
Capital Expenditure -0.52-1.02-0.62-0.07-1.50-0.13-0.07-0.48-0.46-0.45-0.43-0.42
Capital Expenditure (%)
Free Cash Flow -35.08-31.35-21.09-19.60-19.62-12.11-5.97-15.68-15.12-14.59-14.07-13.57

Weighted Average Cost Of Capital

Share price $ 2.54
Beta 0.410
Diluted Shares Outstanding 1.38
Cost of Debt
Tax Rate -231.62
After-tax Cost of Debt 5.00%
Risk-Free Rate
Market Risk Premium
Cost of Equity 5.723
Total Debt 11.19
Total Equity 3.52
Total Capital 14.70
Debt Weighting 76.09
Equity Weighting 23.91
Wacc

Build Up Free Cash Flow

Year
A/P
2013
Actual
2014
Actual
2015
Actual
2016
Actual
2017
Actual
2018
Actual
2019
Actual
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
Revenue 12.207.6011.6611.386.416.657.006.756.516.286.055.84
Operating Cash Flow -34.56-30.33-20.47-19.53-18.13-11.98-5.91-15.20-14.66-14.14-13.63-13.15
Capital Expenditure -0.52-1.02-0.62-0.07-1.50-0.13-0.07-0.48-0.46-0.45-0.43-0.42
Free Cash Flow -35.08-31.35-21.09-19.60-19.62-12.11-5.97-15.68-15.12-14.59-14.07-13.57
WACC
PV LFCF -14.91-13.67-12.54-11.50-10.54
SUM PV LFCF -63.17

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 5.17
Free cash flow (t + 1) -14.11
Terminal Value -1,205.80
Present Value of Terminal Value -937.17

Intrinsic Value

Enterprise Value -1,000.33
Net Debt -6.36
Equity Value -993.97
Shares Outstanding 1.38
Equity Value Per Share -718.18